Drug Information

Drug General Information
Drug ID
D06DHB
Former ID
DNCL003525
Drug Name
E7016
Drug Type
Small molecular drug
Indication Melanoma [ICD9: 172; ICD10:C43] Phase 2 [523915]
Company
Eisai
Structure
Download
2D MOL

3D MOL
Formula
C20H19N3O3
Canonical SMILES
C1CN(CCC1O)CC2=CC3=C(C=C2)OC4=CC=CC5=C4C3=NNC5=O
InChI
1S/C20H19N3O3/c24-13-6-8-23(9-7-13)11-12-4-5-16-15(10-12)19-18-14(20(25)22-21-19)2-1-3-17(18)26-16/h1-5,10,13,24H,6-9,11H2,(H,22,25)
InChIKey
HAVFFEMDLROBGI-UHFFFAOYSA-N
PubChem Compound ID
11660296
PubChem Substance ID
16763954, 23760756, 79382785, 136350013, 141169352, 164038807, 172650555, 198985709, 227542509, 248200962
Target and Pathway
Target(s) Poly ADP ribose polymerase (PARP) Target Info Modulator [1572591]
References
Ref 523915ClinicalTrials.gov (NCT01605162) Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma. U.S. National Institutes of Health.
Ref 1572591Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.